CN1972917B - Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof - Google Patents

Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof Download PDF

Info

Publication number
CN1972917B
CN1972917B CN2005800208831A CN200580020883A CN1972917B CN 1972917 B CN1972917 B CN 1972917B CN 2005800208831 A CN2005800208831 A CN 2005800208831A CN 200580020883 A CN200580020883 A CN 200580020883A CN 1972917 B CN1972917 B CN 1972917B
Authority
CN
China
Prior art keywords
amino
compound
methyl
pyridyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2005800208831A
Other languages
Chinese (zh)
Other versions
CN1972917A (en
Inventor
孙飘扬
吕爱锋
杨保海
胡春勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNA2005101074022A external-priority patent/CN1939910A/en
Application filed by Individual filed Critical Individual
Publication of CN1972917A publication Critical patent/CN1972917A/en
Application granted granted Critical
Publication of CN1972917B publication Critical patent/CN1972917B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The present invention provides aminopyrimidine compounds of formula (I) and their salts, wherein R1, R2, R3, R4, R5, R6, Q, Z, L, m, n are defined as the description, the methods for preparation thereof, the uses thereof and the pharmaceutical compositions comprising the effective amount of compounds of formula (I). The compounds of formula (I) and their salts can be used as protein kinase inhibitors.

Description

Amino-metadiazine compound and salt thereof and its preparation method and pharmaceutical use
Technical field
The present invention relates to general formula and be the amino-metadiazine compound and the salt thereof of (I), and its preparation method and this compound separately or and other drug unite the application of use in treatment cell hyperplastic disease (as cancer).
Background technology
In the chronic myelogenous leukemia people more than 95%, because chromosome translocation produces the BCR-ABL fusion rotein, cause high expression level ABL tyrosine kinase activity, therefore, this class patient becomes the indication of imatinib (Imatinib) target administration.People's chronic myelogenous leukemia K562 cell expressing Bcr-Abl albumen, so the present invention is the commonly used cell model of research at the BCR-ABL medicine.
In the prior art, people adopt for example Interferon Alfa-2a treatment chronic myelogenous leukemia, and this medicine has broad-spectrum antiviral, antitumor and immunoloregulation function.Interferon, rabbit combines with cell surface receptor, inducing cell produces multiple antiviral protein, suppress virus and in cell, breed, improve immunologic function and comprise the phagocytic function that strengthens scavenger cell, strengthen lymphocyte cytotoxicity of target cell and the function of NK cell sexual cell.
Recently, Gleevec has another name called the front medicine that imatinib (imatinib) becomes the treatment chronic myelocytic leukemia, but has produced resistance after some patient's medication.New research says, perhaps the Gleevec of the s-generation can help the patient that develops immunity to drugs.Thereby this medicine and BCR-ABL are in conjunction with having hindered its activity, and BCR-ABL is an enzyme that promotes leukemia cell's growth.As a rule, drug-fast generation is because variation has taken place BCR-ABL, has made the alteration of form of enzyme, and medicine can not combine with it.Neil P.Shah and colleague have isolated an imatinib variation that is called as BMS-354825, and this makes a variation to low with BCR-ABL enzyme bonded selectivity.The experiment that the article author makes of the medullary cell from the leukaemic of leukemia mouse pattern and cultivation shows that BMS-354825 is more effective than imatinib, and can do with most imatinib-resistant, and does not have tangible toxicity.(imatinib-resistant of about 15-20% is caused by the another kind variation, and new drug is invalid to these cases.) BMS-354825 now entered the first phase clinical stage.(Overriding?ImatinibResistance?With?a?Novel?ABL?Kinase?Inhibitor，Neil?P.Shah，et?al.)。
Before not finding imatinib, the activated medicine of the positive myeloid leukemia of Philadelphia chromosome (Ph) (CML) there is IFN-α, cytosine arabinoside and homoharringtonine (HHT) can separately or be united use.But also there is unsatisfactory effect in these already used medicines.
Summary of the invention
In order to overcome the deficiencies in the prior art, the object of the present invention is to provide a kind of amino-metadiazine compound and salt thereof; Another object of the present invention is to provide a kind of method for preparing amino-metadiazine compound and salt thereof; Another purpose of the present invention is to provide a kind of this compound and salt thereof to unite the application of use in treatment cell hyperplastic disease (as cancer) separately or with other drug.
The objective of the invention is to reach, the present invention relates to a kind of general formula amino-metadiazine compound and salt thereof for (I) by following technical scheme:
Figure G60219652150141000D000021
In the formula,
R 1Be selected from and be substituted or do not have substituted aryl, heterocyclic aryl or heterocycle, substituting group to be selected from halogen atom, C1-4 straight or branched alkyl, amino, alkoxyl group, cycloalkyl;
R 2And R 3Be independently selected from hydrogen, halogen atom, amino, alkylamino, dialkyl amido, cyano group, nitro, hydroxyl, alkoxyl group, halogenated alkoxy; Or be substituted or do not have substituted alkyl, cycloalkyl, thiazolinyl, alkynyl, aryl, heterocyclic aryl, aralkyl and heterocycle aralkyl, substituting group to be selected from halogen atom, C1-4 straight or branched alkyl, amino, alkoxyl group, nitro; Or R 2, R 3The 4-7 unit that coupled carbon atom forms is substituted or does not have substituted carbocyclic ring or heterocycle, and substituting group is selected from halogen atom, amino, alkylamino, dialkyl amido, cyano group, nitro, hydroxyl, alkoxyl group, halogenated alkoxy;
R 4Be selected from hydrogen, halogen atom, amino, alkylamino, dialkyl amido, cyano group or be substituted or do not have substituted alkyl, cycloalkyl, thiazolinyl, alkynyl, substituting group is selected from halogen atom, amino, hydroxyl;
R 5Be selected from hydrogen, halogen atom, nitro, cyano group, hydroxyl, alkoxyl group, methylene-dioxy, halogenated alkoxy, amino or be substituted or do not have substituted alkyl, cycloalkyl, thiazolinyl, alkynyl, aryl, heterocyclic aryl, substituting group is selected from halogen atom, amino, hydroxyl;
R 6Be selected from hydrogen or be substituted or do not have substituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclic aryl, heterocycle aralkyl, heterocycle, Heterocyclylalkyl, substituting group is selected from halogen atom, amino, C1-4 alkyl;
M=0,1,2 or 3;
N=0,1,2 or 3;
Q is selected from aryl, heterocyclic aryl or heterocycle;
Z is selected from aryl, heterocyclic aryl or heterocycle;
L is selected from
(1)-NR 7CO-
(2)-CONR 8-
(3)NR 9SO 2-
(4)-SO 2NR 10-
(5)-NR 11COO-
(6)-NR 12CONR 13-
(7)-OCONR 14-
R wherein 7, R 8, R 9, R 10, R 11, R 12, R 13And R 14Be selected from hydrogen, be substituted or do not have substituted alkyl, cycloalkyl, substituting group is selected from halogen atom, amino, hydroxyl.
The objective of the invention is further to be reached by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in R 1Be selected from and be substituted or do not have substituted heterocyclic aryl, preferably be substituted or do not have substituted hexa-member heterocycle aryl, more preferably be substituted or do not have substituted pyridine ring, substituting group to be selected from halogen atom, C1-4 straight or branched alkyl.
The objective of the invention is further to be reached by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in R 2And R 3Be selected from hydrogen, halogen atom, amino, alkylamino, cyano group, nitro, be substituted or do not have substituted alkyl, cycloalkyl, substituting group is selected from halogen atom; Preferred hydrogen or halogen atom, wherein halogen atom refers to fluorine, chlorine, bromine, iodine atom.
The objective of the invention is further to be reached by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in R 4Be selected from and be substituted or do not have substituted alkyl, cycloalkyl, thiazolinyl, alkynyl, preferably be substituted or do not have substituted alkyl, more preferably carbon atom is being substituted of 1-4 or does not have substituted alkyl, and substituting group is selected from halogen atom, amino.
The objective of the invention is further to be reached by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in R 5Be selected from hydrogen, halogen atom, nitro or be substituted or do not have substituted alkyl, cycloalkyl, thiazolinyl, an alkynyl; Preferred hydrogen, halogen atom or be substituted or do not have substituted alkyl, cycloalkyl, substituting group is selected from halogen atom or hydroxyl.
The objective of the invention is further to be reached by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in R 6Be selected from heterocyclic aryl, heterocycle aralkyl, heterocycle and Heterocyclylalkyl, above group can be substituted or not be substituted, and preferably is substituted or does not have substituted heterocyclic aryl, a Heterocyclylalkyl, the preferred C1-4 alkyl of substituting group.
The objective of the invention is further to be reached by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in that m and n are independently selected from 0,1,2,3.
The objective of the invention is further to be reached by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in that Q is selected from aryl, heterocyclic aryl or heterocycle, preferred aryl groups or heterocyclic aryl; Z is selected from aryl, heterocyclic aryl or heterocycle, preferred aryl groups or heterocyclic aryl.
The objective of the invention is further to be reached by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in that L is selected from (1)-NR 7CO-, (2)-CONR 8-, (3)-NR 9SO 2-, (4)-SO 2NR 10-, (5)-NR 11COO-, preferred (1)-NR 7CO-or (2)-CONR 8-; R 7, R 8, R 9, R 10, R 11Be selected from alkyl or hydrogen, preferred hydrogen.
The objective of the invention is further to reach by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in referring to (R), (S) or (RR), single enantiomer form such as (SS) or to be rich in compound and the salt thereof that enantiomeric form exists.
The objective of the invention is further to reach by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in described compound can with the acid of certain amount (as etc. amount) salify, used acid is selected from organic acid (as acetate, trichoroacetic acid(TCA), propionic acid, butyric acid, aspartic acid, tosic acid, toxilic acid, lactic acid) or mineral acid (example hydrochloric acid, sulfuric acid, phosphoric acid, methylsulfonic acid), preferred hydrochloric acid and methylsulfonic acid.
The objective of the invention is further to reach by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in described compound can with the alkali of certain amount (as etc. amount) salify, the salt that is become comprises and basic metal (as lithium, sodium, potassium etc.), alkaline-earth metal (as magnesium, calcium etc.) or quaternary ammonium (as NY 4, wherein Y refers to that carbon atom is the 1-4 alkyl) and the salt that become.
The objective of the invention is further to be reached by following technical scheme, above-mentioned general formula is the compound and the salt thereof of (I), be characterized in that described compound comprises:
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-] benzamide,
4-((4-ethyl-1-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-] benzamide,
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-fluoro-benzamide,
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-chloro-benzamide,
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-(trifluoromethyl)-benzamide,
6-methyl-N-[3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) phenyl]-5-[4-(3-pyridyl)-2-(pyrimidyl) amino] nicotine,
6-methyl-N-[4-((4-methylpiperazine-1-yl) methyl-3-(trifluoromethyl) phenyl)-5-[4-(3-pyridyl)-2-(pyrimidyl) amino] nicotine,
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[5-methyl-4-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-2-]-3-(trifluoromethyl)-benzamide,
5-methyl-N-[4-((4-methylpiperazine-1-yl) methyl-3-(trifluoromethyl) phenyl)-4-[4-(3-pyridyl)-2-(pyrimidyl) amino] picolinamide,
5-methyl-N-[3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) phenyl]-4-[4-(3-pyridyl)-2-(pyrimidyl) amino] picolinamide.
Another object of the present invention is further reached by following technical scheme, the invention provides a kind of preparation general formula for the compound of (I) and the method for salt thereof, is characterized in comprising the steps:
(A) with general formula be the compound reaction of the compound of (II) and general formula under alkaline condition for (III), general formula be the compound of (IV):
Figure G60219652150141000D000051
(B) general formula is got the compound that general formula is (I) for the compound of (IV) and general formula for compound condensation reaction in the presence of condensing agent of (V).
Figure G60219652150141000D000052
R wherein 1, R 2, R 3, R 4, R 5, R 6, Q, L, m, n such as front define; L ', M ' refer to the group of phase mutual energy generation condensation reaction, as amino, carboxylic acid group, anhydride group, ester group, acid halide group etc., and preferred amino, carboxylic acid group or acid halide group; Also can refer to change into the organic group of amino, carboxylic acid group or acid halide group, as nitro, ester group through conventional method; R 15Refer to easy leavings group, be selected from halogen atom (as fluorine, chlorine, bromine, iodine) or methylsulfonyl, ethylsulfonyl, p-toluenesulfonyl etc.
Another object of the present invention is further reached by following technical scheme, the invention provides a kind of preparation general formula for the compound of (I) and the method for salt thereof, is characterized in
(A) when preparation compound (IV), used alkali is selected from organic bases (as n-Butyl Lithium, sodium methylate, sodium ethylate, potassium tert.-butoxide) or mineral alkali (as sodium, sodium hydroxide, potassium hydroxide, sodium amide, sodium hydrogen), preferred sodium hydrogen.
(B) when preparation compound (I), when reaction is carboxylic acid group and amino condensation, condensing agent is N, N-dicyclohexylcarbodiimide, N, N-DIC, N, the mixture that mixture that N-diethyl carbodiimide, triphenyl phosphorus and diethylazodicarboxylate form or triphenyl phosphorus and diisopropyl azo-2-carboxylic acid form etc., preferred N, N-dicyclohexylcarbodiimide; When reaction was acid halide group and amino condensation, condensing agent was mineral alkali (as yellow soda ash, salt of wormwood, lime carbonate) or organic bases (as triethylamine, pyridine, 4-dimethylamino pyridine, tripropyl amine, Tributylamine), preferred pyridine or triethylamine.
Another purpose of the present invention is further reached by following technical scheme, the invention provides a kind of this compound and salt thereof and unites the application of use in treatment cell hyperplastic disease (as cancer) separately or with other drug.
In the present invention, " alkyl " refers to side chain or straight chain representative examples of saturated aliphatic hydrocarbon-based; Preferred carbon atom is 1-10 side chain or a straight chain representative examples of saturated aliphatic alkyl, as methyl, ethyl, propyl group, sec.-propyl, butyl, the tertiary butyl, isobutyl-, amyl group, hexyl, heptyl, octyl group etc.; " cycloalkyl " refers to contain monocyclic representative examples of saturated aliphatic hydrocarbon-based, and preferred carbon atom is 3-10 a cycloalkyl, as cyclopropyl, methyl-cyclopropyl, 2,2-dimethyl-cyclobutyl, ethyl-cyclopentyl, cyclohexyl etc.; In " C1-C6 aralkyl " and " C1-C6 heterocycle aralkyl ", " C1-C6 " refers to the moieties carbonatoms.
In the present invention, " thiazolinyl " refers to that carbon atom is 2-10, contains side chain, straight chain or the ring-type non-aromatic hydrocarbon group of a carbon-carbon double bond at least, as vinyl, propenyl, butenyl, tetrahydrobenzene etc.At " C2-C6 thiazolinyl " middle finger thiazolinyl carbon atom is 2-6.
In the present invention, " alkynyl " refers to that carbon atom is 2-10, contains carbon carbon triple-linked side chain, straight chain or a ring-type hydrocarbon group at least, as ethynyl, proyl, butynyl, 3-methyl butynyl etc.At " C2-C6 alkynyl " middle finger alkynyl carbon atom is 2-6.
In the present invention, " alkoxyl group " refers to that by oxygen connection, carbon atom be individual ring-type or non-annularity alkyl of 1-10.
In the present invention, " aryl " refers to any stable monocycle or dicyclo, and wherein the carbon atom of each ring is not more than 7 and at least one ring and is aromatic nucleus, as phenyl, Nai Ji, tetrahydrochysene how, phenylbenzene etc.If aryl be dicyclo and wherein a ring then react by aromatic nucleus and connect for non-aromatic ring.
In the present invention, " halogen atom " refers to fluorine, chlorine, bromine and iodine.
In the present invention, " heterocyclic aryl " refers to stable monocycle or dicyclo, and wherein each ring carbon atom is not more than 7 and at least one ring for aromatic nucleus and contain 1-4 heteroatoms, and heteroatoms is selected from O, N, S.By this definition, " heterocyclic aryl " comprise but and non-limiting following kind: furyl, thienyl, pyrryl, thiazolyl, thiadiazolyl group, isothiazolyl, imidazolyl, triazolyl, triazinyl, pyrazinyl, pyridazinyl, pyridyl, pyrimidyl, benzothienyl, benzofuryl, indyl, benzotriazole base, quinolyl, quinoxalinyl, isoquinolyl, tetrahydric quinoline group etc.Contain the N atomic time in heterocyclic aryl, " heterocyclic aryl " also comprises its N-oxygen derivative.If heterocyclic aryl be dicyclo and wherein a ring then react by aromatic nucleus or contain heteroatomic ring and connect for non-aromatic ring or when not containing heteroatoms.
In the present invention, " heterocycle " refers to the monocycle of 4-8 atom, the dicyclo of a 7-12 atom or three rings of 1-16 atom; Ring can be saturated or unsaturated, is made up of carbon atom and one or more heteroatoms, and wherein heteroatoms is selected from N, O, S, when N and S are heteroatoms, and can be oxidized; When N can be by quaternized during for heteroatoms.As long as can obtain stable structure, reaction can be connected by any heteroatoms or carbon atom.When heterocycle had substituting group, substituting group can be connected in the ring on any atom.It comprises benzimidazolyl-, benzofuryl, the benzopyrazoles base, the benzotriazole base, benzothienyl, carbazyl, carbolinyl, furyl, imidazolyl, indolinyl, indyl, indazolyl, isobenzofuran-base, pseudoindoyl, isoquinolyl, isothiazolyl, how pyridyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, the pyridopyridine base, pyridyl, pyrimidyl, pyrryl, quinazolyl, quinolyl, quinoxalinyl, THP trtrahydropyranyl, tetrazyl, the tetrazolo pyridyl, thiadiazolyl group, thiazolyl, thienyl, triazolyl, six hydrogen azepine bases, piperazinyl, piperidyl, pyrrolidyl, morpholinyl, the parathiazan base, the dihydrobenzo imidazolyl, dihydro benzo furyl, the dihydrobenzo thienyl, the dihydrofuran base, the glyoxalidine base, indolinyl, the dihydro isothiazolyl, the dihydro pyrazinyl, the pyrazoline base, the dihydropyridine base, the dihydro-pyrimidin base, the pyrrolin base, the dihydroquinoline base, the dihydro tetrazyl, the thiodiazoline base, dihydro-thiazolyl, the dihydro-thiophene base, the dihydro triazolyl, the dihydro azetidinyl, the methylenedioxy benzene formyl radical, tetrahydrofuran base, tetrahydro-thienyl, thiazinyl, dioxy thiadiazine base, dioxy thiadiazoles alkyl, different dioxy thiadiazoles alkyl etc.; " heterocycle " also comprises following dicyclic compound, as imidazoles [4,5-b] pyridyl, glyoxalidine [4,5-b] pyridyl, pyrazoline [4,3-c] pyridyl, pyrazoline quinoline [4,3-c] pyridyl, tetrahydro-pyrazole quinoline [4,3-c] pyridyl, pyrroles [1,2-a] pyrazinyl, pyrrolin [1,2-a] pyrazinyl, Pyrrolidine [1,2-a] pyrazinyl, the cinnolines base, purine radicals, 1, the 6-naphthyridinyl, 1, the 8-naphthyridinyl, imidazoles [1,2-a] pyrimidyl, 2,3-glyoxalidine [2,1-b] [1,3] thiazolyl, benzene azepine base, dihydrobenzene azepine base, the benzodiazepine base, dihydrobenzo diaza base, tetrahydro benzo diaza base etc.; " heterocycle " also comprises following tricyclic compound, as phenothiazinyl, carbazyl, β-carbazyl, phenazinyl etc.
Abovementioned alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, heterocyclic aryl and heterocyclic radical also can be substituted, its substituting group comprise but and non-limiting following kind: hydroxyl, alkyl, haloalkyl, halogen, cyano group, nitro, carbonyl, ester group, amino, alkoxyl group, alkylamino, dialkyl amido etc.
Gained compound of the present invention and salt thereof can be by oral, corium or parenteral route (as by injection, suction, spraying, hypogloeeis, rectum or vagina) administrations." drug administration by injection " comprises intravenous injection, joint injection, intramuscular injection, subcutaneous injection, the injection of non-enteron aisle and transfusion.The corium administration comprises the part or intersects administration.Oral medication prepares according to method well-known to those skilled in the art, also one or more auxiliary agents can be arranged in this type of preparation, as thinner, sweeting agent, seasonings, toner and sanitas.
In tablet, active ingredient and nontoxic, pharmaceutically useful mixed with excipients.These vehicle comprise: inert diluent (as lime carbonate, yellow soda ash, lactose, calcium phosphate or sodium phosphate), granulation or disintegrating agent (as W-Gum, alginic acid) and tackiness agent (as Magnesium Stearate, stearic acid, talcum).Tablet is dressing not, thereby also can prolong effective drug duration with decomposition and the absorption that known method dressing delays in gi tract, as using stearin or Stearic diglyceride.These compounds also can be prepared into pattern solid-state, snap-out release.
In hard capsule, active ingredient and inert solid diluent such as lime carbonate, calcium phosphate or potter's clay mix; In soft capsule, active ingredient and water or oily media such as peanut oil, paraffin or mixed with olive oil.
In water suspending agent, active ingredient and can be fit to medicinal mixed with excipients.These vehicle have suspension agent (as hydroxy-methyl cellulose sodium, methylcellulose gum, hydroxypropyl-methylcellulose gum, sodiun alginate, polyvinylpyrrolidone, tragacanth gum, gum arabic), dispersion agent or wetting agent [comprise the condenses (as polyoxyethylene stearic acid ester) of spontaneous phosphatide (as Yelkin TTS) or alkylene oxide and lipid acid or the condenses of ethylene oxide and long chain aliphatic alcohol (as 17 carbon ethylene oxy hexadecanols) or ethylene oxy and by lipid acid and hexitol the derive condenses (as the polyoxyethylene sorbitol monoleate) of the part ester that obtains or ethylene oxy and by the derive condenses (as the polyethylene dehydrated sorbitol mono-fatty acid ester) of the part ester that obtains of lipid acid and hexose acid anhydride.Described water suspending agent also can contain one or more sanitass (as ethyl p-hydroxybenzoate, propylparaben); One or more toners; One or more perfume compound and one or more sweeting agents (as sucrose or asccharin).
But the dispersed powders of suitable preparation water suspending agent and particle are by preparing water, active ingredient and dispersion agent or wetting agent, suspension agent and the mixing of one or more sanitass.Also can be to wherein adding other vehicle such as sweeting agent, toner, perfume compound.
The compound of gained general formula of the present invention (I) and salt thereof also can be prepared into non--water liquid preparation.Oil-suspending agent can be suspended in active ingredient in vegetables oil (as peanut oil, sweet oil, sesame oil) or the mineral oil (as whiteruss); Can contain thickening material (as beeswax, paraffinum durum or hexadecanol) in the oil-suspending agent; Also can add the mouthfeel that sweeting agent and perfume compound increase preparation; For increasing stability of formulation, can add oxidation inhibitor (as xitix).
The compound and the salt thereof of gained general formula of the present invention (I) also can be prepared into oil-water emulsion.Oil phase is selected from vegetables oil (as sweet oil, peanut oil) or mineral oil (as whiteruss) or said mixture.Emulsifying agent is selected from natural gum (as tragacanth gum, gum arabic) or natural phospholipid (as soybean, Yelkin TTS) or by lipid acid and hexose acid anhydride derive the part ester (as sorbitol monooleate) that obtains or the product (as octadecanoic acid ester of polyethylene glycol) of above-mentioned ester and ethylene oxy condensation.Also can contain sweeting agent and perfume compound in the milk sap.
Sweeting agent is selected from glycerine, propylene glycol, sorbyl alcohol or sucrose in syrup and the elixir.Also can contain negative catalyst, sanitas, perfume compound and toner in this class preparation.
The compound of gained general formula of the present invention (I) and salt thereof also can be prepared into the suppository of rectum or vagina administration.This suppository is by preparing active ingredient and suitable nontoxic mixed with excipients, and selected vehicle is solid at normal temperatures, thereby but in rectum or vagina, melt and become liquid and discharge medicine, as theobroma oil and polyoxyethylene glycol.
The compound of gained general formula of the present invention (I) and salt thereof also can be with the anti-corium administrations of method well known to those skilled in the art.For example, in volatile solvent, solution or suspension, penetration enhancers and the additive well known to those skilled in the art of resulting compound (I) are mixed mutually, and after the aseptically process, the gained mixture is prepared into required preparation by the program of knowing and certain dosage; In addition, after emulsifying agent or water treatment, the solution or the suspension of compound (I) can be prepared into lotion or ointment.
Through skin transmission system solvent for use is well-known to those skilled in the art, comprises lower alcohol (as ethanol or Virahol), lower ketones (as acetone), low-carbon carboxylate (as ethyl acetate), polarity ethers (as tetrahydrofuran (THF)), rudimentary hydrocarbons (as normal hexane, hexanaphthene or benzene) or halo hydrocarbons (as methylene dichloride, chloroform, Refrigerant R 113); Solvent for use also comprises one or more mixed solvents that are selected from lower alcohol, lower ketones, low-carbon carboxylate, polar ether, rudimentary hydrocarbons, the rudimentary hydrocarbons of halo.
Through the used penetration enhancers of skin transmission system is well-known to those skilled in the art, comprises that monohydroxy or polyhydroxy-alcohol are (as ethanol, propylene glycol or benzylalcohol), saturated or undersaturated C8-C18 Fatty Alcohol(C12-C14 and C12-C18) (as lauryl alcohol or hexadecanol), saturated or undersaturated C8-C18 lipid acid (as stearic acid), carbon atom is no more than 24 saturated or unsaturated ester (as acetate, caproic acid, lauric acid, TETRADECONIC ACID, stearic acid or Palmiticacid and methyl alcohol, ethanol, propyl alcohol, butanols, isopropylcarbinol, the ester that the trimethyl carbinol or single glycerine generated) the formed diester of saturated or undersaturated dicarboxylic acid is (as Wickenol 116, diisobutyl adipate, Wickenol 117, isopropyl maleate; Penetration enhancers also comprises phospholipid derivative (as Yelkin TTS or kephalin), terpenes, ammonia, ketone, urea and derivative thereof and ethers (as isosorbide dimethyl ether, diethylene glycol monoethyl ether); Suitable penetration enhancers also comprises and is selected from the mixture that monohydroxy or polyhydroxy-alcohol, saturated or unsaturated C8-C18 Fatty Alcohol(C12-C14 and C12-C18), saturated or unsaturated C8-C18 lipid acid, carbon atom are no more than one or more materials in 24 saturated or unsaturated ester, the formed diester of saturated or undersaturated dicarboxylic acid, phospholipid derivative, terpenes, ammonia, ketone, urea and derivative thereof, the ether.
Through skin transmission system adhesive therefor is well-known to those skilled in the art, comprise polyacrylic ester, silicone resin, Polyurethanes, segmented copolymer, styrene-butadiene copolymer, natural or synthetic rubber, Mierocrystalline cellulose, polythene derivative and silicate also can be as the constituents of skeleton.In addition, thus also can add the viscosity that additive such as tackifying resin or oil increase skeleton.
The compound and the salt thereof of gained general formula of the present invention (I), the preferred 0.01-200mg/kg of its oral administration daily dosage portion; The preferred 0.01-200mg/kg of its drug administration by injection daily dosage portion (as intravenous injection, intramuscular injection, subcutaneous injection, the injection of non-enteron aisle or transfusion); Its rectum or the preferred 0.01-200mg/kg of vagina administration daily dosage portion; The preferred 0.1-200mg of its topical daily dosage portion, every day, administration was 1-4 time; The preferred 0.01-200mg/kg of its anti-corium administration concentration; The preferred 0.01-10mg/kg of its inhalation daily dosage portion, wherein " mg " represents the weight unit of active ingredient in the pharmaceutical composition, " kg " represents human weight unit.
Certainly, just as known to those skilled in the art, the dosage of medicine depends on multiple factor, comprise but and non-limiting following factor: the combination of the mode of the activity of used specific compound, patient's age, patient's body weight, patient's healthy state, patient's sex, patient's diet, time of administration, administration, excretory speed, medicine etc.; In addition, Zui Jia therapeutic modality can be verified according to traditional treatment plan as pattern, the daily dosage portion of compound (I) or the kind of pharmaceutically acceptable salt of treatment.
On the other hand, the invention provides a kind of this compound and salt thereof and unite the application of use in treatment cell proliferative diseases (as cancer) separately or with other drug.Can and compound provided by the present invention and salt thereof the antineoplastic agent of uniting use comprise polynucleotide, polypeptide, biosimulation medicine, alkaloid, alkylating agent, antitumor antibiotics, metabolic antagonist, hormone, platinic compound and antitumor drug bonded monoclonal antibody, toxin and or radioactive nuleus, biological response modifier (as Interferon, rabbit), immunotherapy agent, hematopoiesis growth factor, gene therapeutic agents, antisense therapy agent, nucleosides, anti-tumor vaccine etc.Preferred antineoplastic agent is induced or is stimulated apoptosis (apoptosis) agent, apoptosis-induced (apoptosis) agent comprise but and non-limiting following kind: radiation, kinase inhibitor is (as epidermis growth factor receptor kinase inhibitor, blood vessel growth factor receptor kinase inhibitor, thrombocyte growth factor receptor kinase inhibitor and Bcr-abl kinase inhibitor such as STI-157 derive, Gleevec), also preferred antisense molecule, antibody (as Hercepin and Rituxan), estrogen antagonist agent (as raloxifene and tamoxifen), anti-male hormones agent is (as flutamide, bicalutamide, finasteride, aminoglutethamide, ketoconazole and corticosteroids), cox 2 inhibitor is (as Celecoxib, meloxicam, NS-398, on-steroidal anti-inflammatory drug and cancer chemotherapeutic drug (as irinotecan), CPT-11, fludarabine, dacarbazine, dexabethasone, mitoxantrone, Mylotarg, VP-16, cis-platinum, 5-FU, Doxrubicin, TAXOTERE, the cell marking molecule, ceramide, cytokine, staurosprine etc.
The present invention relates to general formula and be the compound of (I) and the preparation method of salt thereof, its preparation method specifically comprises:
Stage A: this stage comprises compound (II) and compound (III) prepared in reaction compound (IV).Originally be reflected in the alkaline environment and carry out, used alkali is selected from organic bases (as pyridine, triethylamine, hexahydropyridine, N methyl piperazine, 4-Dimethylamino pyridine etc.) or mineral alkali (as yellow soda ash, salt of wormwood, sodium bicarbonate, saleratus, sodium methylate, sodium ethylate, sodium amide, sodium hydrogen, n-Butyl Lithium etc.), institute's alkali charge is controlled at 1-10 times of compound (II) amount, and preferred 1-3 doubly; This temperature of reaction is from-80 ℃ to 100 ℃, preferred 0 ℃ to 60 ℃; This reacts the used time and depends on compound (II) and (III) type, selected solvent and the temperature of reaction etc., generally is controlled at 1min-72hrs, preferred 15min-24hrs.
Stage B: this stage comprises that compound (IV) and compound (V) condensation reaction prepare compound (I).When condensation reaction is carried out between acid and amino, used condensing agent is selected from N, N-dicyclohexylcarbodiimide, N, N-DIC, N, the mixture that mixture that N-diethyl carbodiimide, triphenyl phosphorus and diethylazodicarboxylate form or triphenyl phosphorus and diisopropyl azo-2-carboxylic acid form etc., preferred N, the N-dicyclohexylcarbodiimide; Solvent for use is selected from the mixture of toluene, benzene, methylene dichloride, chloroform, four feelings furans or above-mentioned solvent composition etc., preferred methylene dichloride; Temperature of reaction is controlled at-80 ℃ to 100 ℃, preferred 0 ℃ to 60 ℃; Reacting the used time depends on compound (IV) and (V) type, selected solvent and the temperature of reaction etc., generally is controlled at 1min-72hrs, preferred 15min-24hrs.When condensation reaction is carried out between carboxylic acid halides and amino, used condensing agent is selected from organic bases (as pyridine, triethylamine, hexahydropyridine, N methyl piperazine, 4-Dimethylamino pyridine etc.) or mineral alkali (as yellow soda ash, salt of wormwood, sodium bicarbonate, saleratus, sodium methylate, sodium ethylate, sodium amide, sodium hydrogen, n-Butyl Lithium etc.), institute's alkali charge is controlled at 1-10 times of compound (IV) amount, and preferred 1-3 doubly; This temperature of reaction is from-80 ℃ to 100 ℃, preferred 0 ℃ to 60 ℃; This reacts the used time and depends on compound (II) and (III) type, selected solvent and the temperature of reaction etc., generally is controlled at 1min-72hrs, preferred 15min-24hrs.
Accompanying drawing describes in detail
Fig. 1: the amino-metadiazine compound drug level is to children's grain leukemia HL-60 cell proliferation inhibition rate graph of a relation morning.
Fig. 2: the amino-metadiazine compound drug level is to people's myelogenous leukemia K562 cell proliferation inhibition rate graph of a relation.
Fig. 3: amino-metadiazine compound is to people's myelogenous leukemia K562, children's grain leukemia HL-60 cell inhibitory effect figure early.
Fig. 3-a: people's myelogenous leukemia K562 cell contrast figure.
Fig. 3-b: the figure of children's grain leukemia HL-60 cell contrast early.
Fig. 3-c:HH-GV-E (0.3uM) is to people's myelogenous leukemia K562 cell inhibitory effect figure.
Fig. 3-d:HH-GV-E (10uM) is to children's grain leukemia HL-60 cell inhibitory effect figure morning.
Fig. 3-e:HH-GV-F (0.03uM) is to people's myelogenous leukemia K562 cell inhibitory effect figure.
Fig. 3-f:HH-GV-F (10uM) is to children's grain leukemia HL-60 cell inhibitory effect figure morning.
Fig. 3-g: Compound I matinib (0.3uM) is to people's myelogenous leukemia K562 cell inhibitory effect figure.
Fig. 3-h: Compound I matinib (10uM) is to children's grain leukemia HL-60 cell inhibitory effect figure morning.
Fig. 4: HH-GV-E, HH-GV-F, Gleevec are to human granulocyte leukemia K 562 Nude Mice
Fig. 5: HH-GV-E, HH-GV-F, Gleevec are to the figure that influences of lotus knurl nude mouse body weight.
Fig. 6: HH-GV-E, HH-GV-F, Gleevec are to the curative effect tumour photo of human granulocyte leukemia K 562 Nude Mice.
Fig. 7 .HH-GV-678, Gleevec are to the curative effect of human granulocyte leukemia K 562 Nude Mice
Fig. 8 .HH-GV-678, Gleevec are to the influence of lotus knurl nude mouse body weight
Embodiment
In order to illustrate in greater detail the present invention, provide following preparation example.But scope of the present invention is not to be defined in this.
Embodiment 1
N-(the preparation of 5-nitro-2-picolyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE
2-methylsulfonyl-4-(3-pyridyl) pyrimidine (3.0 gram), 2-methyl-3-amino-5-nitropyridine (5.0 gram) and DMF (50 milliliters) are put in the reaction flask, be cooled to 0-5 ℃, add sodium hydrogen (60%, 2.3 gram), rose to room temperature reaction naturally 6 hours.In reaction solution, add each 50 milliliters in chloroform and water, layering, water layer is with counter the carrying of chloroform (2 * 100 milliliters), merge organic layer, drying is filtered, concentrate to do, column chromatography purification gets N-(5-nitro-2-picolyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE: 5.2 grams.
Embodiment 2
N-(the preparation of 5-amino-2-methyl pyridyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE
Method A: (5-nitro-2-picolyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE (3.0 gram), active nickel (0.3 gram) and methyl alcohol (100 milliliters) are put in the reaction flask, and atmospheric hydrogenation is to there not being raw material with N-.Filter, concentrate and do, N-(5-amino-2-methyl pyridyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE: 2.8 grams.
Method B: (5-nitro-2-picolyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE (18 gram), ethanol (180 milliliters), hydrazine hydrate (9 milliliters) and active nickel (0.5 restrains) are put in the reaction flask with N-, back flow reaction 3 hours, filter, filtrate decompression is concentrated into separates out solid, 0 ℃ of placement is spent the night, filter, and the dry N-of getting (5-amino-2-methyl pyridyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE: 15 restrain.
Method C: (5-nitro-2-picolyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE (18 gram) and tetrahydrofuran (THF) (200 milliliters) are put in the reaction flask with N-, be cooled to 0-5 ℃, add lithium aluminium hydride (about altogether 2.2 grams) in batches, insulation reaction 2 hours adds 1N hydrochloric acid and transfers PH=5-6 in reaction solution, extract with methylene dichloride (2 * 100 milliliters), merge organic layer, drying is filtered, concentrate do N-(5-amino-2-methyl pyridyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE: 12 grams.
Embodiment 3
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] ammonia Base] pyridyl-3-]-preparation of benzamide
Method D: 4-(4-methylpiperazine methyl) phenylformic acid (3.2 gram) and sulfur oxychloride (100 milliliters) are put in the reaction flask, be heated to back flow reaction 4 hours, be evaporated to driedly, the gained solid is directly used in down to go on foot and feeds intake.
(5-amino-2-methyl pyridyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE (3.0 gram) is dissolved in the pyridine (80 milliliters), moltenly this drips of solution is added in the above-mentioned acyl chlorides stirred overnight at room temperature after clear with N-.Concentrating under reduced pressure is done, and adds each 100 milliliters of entry and chloroforms in reaction solution, extraction, dry, filter, concentrate and do, column chromatography purification gets 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-benzamide: 4.2 grams.
Method E: with 4-(4-methylpiperazine methyl) phenylformic acid (3.2 gram), N, (5-amino-2-methyl pyridyl-3-)-4-(3-pyridyl)-2-PYRIMITHAMINE (3.0 gram) and methylene dichloride (100 milliliters) are put in the reaction flask, and stirring at room is reacted and spent the night for N-dicyclohexylcarbodiimide (3.0 gram), N-.Filter, filtrate water (2 * 100 milliliters) washing, drying is filtered, and concentrates the dry chromatography purifying and gets 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-benzamide: 4.0 grams.
Embodiment 4
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] ammonia Base] pyridyl-3-]-preparation of benzamide mesylate
Method F: with 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-benzamide (2.0 gram), methylsulfonic acid (0.40 gram) and purified water (100 milliliters) put in the reaction flask, molten clear after-filtration, filtrate lyophilize get 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-the benzamide mesylate: 2.2 grams.
Method G: with 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-benzamide (2.0 gram), methylsulfonic acid (0.40 gram) and methyl alcohol (100 milliliters) puts in the reaction flask, moltenly be evaporated to about 20 milliliters after clear, add the acetone crystallization, filter dry 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[4-methyl-3-[[4-(3-the pyridyl)-2-pyrimidyl that gets] amino]-pyridyl]-the benzamide mesylate: 2.0 grams.
Embodiment 5
4-((4-ethyl-1-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] Pyridyl-3-]-preparation of benzamide
Can be by two kinds of identical method preparations of D, E among the embodiment 3, difference is to replace 4-(4-methylpiperazine methyl) phenylformic acid (3.2 gram) with 4-(4-ethyl piperazidine methyl) phenylformic acid (3.3 gram).
Embodiment 6
4-((4-ethyl-1-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] ammonia Base] pyridyl-3-]-preparation of benzamide mesylate
Can be by two kinds of identical method preparations of F, G among the embodiment 4, difference is with 4-((4-ethyl-1-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-benzamide (2.10 gram) replacement 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-benzamide (2.0 gram).
Embodiment 7
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] Pyridyl-3-]-preparation of 3-fluorobenzamide
Can be by two kinds of identical method preparations of D, E among the embodiment 3, difference is to replace 4-(4-methylpiperazine methyl) phenylformic acid (3.2 gram) with 4-(4-methylpiperazine methyl)-3-fluoro-phenylformic acid (3.3 gram).
Embodiment 8
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] ammonia Base] pyridyl-3-]-preparation of 3-fluorobenzamide mesylate
Can be by two kinds of identical method preparations of F, G among the embodiment 4, difference is with 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-fluoro-benzamide (2.10 gram) replacement 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-benzamide (2.0 gram).
Embodiment 9
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] Pyridyl-3-]-preparation of 3-chloro-benzamide
Can be by two kinds of identical method preparations of D, E among the embodiment 3, difference is to replace 4-(4-methylpiperazine methyl) phenylformic acid (3.2 gram) with 4-(4-methylpiperazine methyl)-3-chloro-phenylformic acid (3.4 gram).
Embodiment 10
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] ammonia Base] pyridyl-3-]-preparation of 3-chloro-benzamide mesylate
Can be by two kinds of identical method preparations of F, G among the embodiment 4, difference is with 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-chloro-benzamide (2.20 gram) replacement 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-benzamide (2.0 gram).
Embodiment 11
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] Pyridyl-3-]-preparation of 3-(trifluoromethyl) benzamide
Can be by two kinds of identical method preparations of D, E among the embodiment 3, difference is to replace 4-(4-methylpiperazine methyl) phenylformic acid (3.2 gram) with 4-(4-methylpiperazine methyl)-3-(trifluoromethyl) phenylformic acid (3.6 gram).
Embodiment 12
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] ammonia Base] pyridyl-3-]-preparation of 3-(trifluoromethyl) benzamide mesylate
Can be by two kinds of identical method preparations of F, G among the embodiment 4, difference is with 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-(trifluoromethyl) benzamide (2.35 gram) replacement 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-benzamide (2.0 gram).
Embodiment 13
6-methyl-N-[3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) phenyl]-5-[4-(3- Pyridyl)-and 2-(pyrimidyl) amino] preparation of nicotine
Method I: with 6-methyl-5-[4-(3-pyridyl)-2-pyrimidinyl-amino] nicotinic acid (30.7 gram, 0.1mol), 3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) aniline (24.1 grams, 0.1mol), triethylamine (83ml) and DMF (800ml) put in the reaction flask, be cooled to 10 ℃, the mixed solution (87.5ml) of the propyl group phosphoric anhydride/DMF of Dropwise 5 0% drips off back room temperature reaction 24 hours.Add saturated ammonium chloride solution in reaction solution, use ethyl acetate extraction three times, drying is filtered, and concentrates and does, and column chromatography gets title compound.
Method II: with 6-methyl-5-[4-(3-pyridyl)-2-pyrimidinyl-amino] nicotinic acid (30.7 gram) and sulfur oxychloride (500ml) put in the reaction flask, was heated to back flow reaction 4 hours, is evaporated to driedly, and the gained solid is directly used in down to go on foot and feeds intake.
3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) aniline (24.1 gram) is dissolved in the pyridine (200 milliliters), moltenly this drips of solution is added in the above-mentioned acyl chlorides stirred overnight at room temperature after clear.Concentrating under reduced pressure is done, and adds each 500 milliliters of entry and chloroforms in reaction solution, extraction, and drying is filtered, and concentrates and does, and column chromatography purification gets title compound.
The preparation of intermediate 3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) aniline
3-fluoro-5-(trifluoromethyl)-benzene cyanogen (17 grams, 89mmol), 4-methylimidazole (22.2 grams, 270mmol) and N,N-dimethylacetamide (80 milliliters) are put in the reaction flask, in 145 ℃ of reactions 19 hours.Concentrating under reduced pressure removes and desolvates, and adds ethyl acetate (200 milliliters), uses salt solution (2 * 200 milliliters) washing successively, drying.Filter, concentrate dried back and get intermediate with ether-sherwood oil recrystallization: 3-(4-methyl isophthalic acid H-imidazoles-1-)-5-(trifluoromethyl)-benzene cyanogen.
To go up step intermediate (16.7 grams, 66mmol), dioxane (300 milliliters) and 1M aqueous sodium hydroxide solution (275 milliliters) and put in the reaction flask, in 95 ℃ of reactions 18 hours.Concentrate to remove and to desolvate, transfer PH to neutral, extract with propyl carbinol (2 * 250 milliliters) with 1M hydrochloric acid, drying, concentrate do intermediate: 3-(4-methyl isophthalic acid H-imidazoles-1-)-5-(trifluoromethyl)-phenylformic acid.
To go up step intermediate (6.8 gram, 25mmol), the trimethyl carbinol (200 milliliters) is put in the reaction flask, adds triethylamine (5.23 milliliters, 37.5mmol), adds phenylbenzene nitrine phosphoric acid (DPPA) (7.6 grams, 27.5mmol) again, in 80 ℃ of reactions 16 hours.Concentrating under reduced pressure removes and desolvates, and adds entry (100 milliliters), extracts with ethyl acetate (2 * 100 milliliters).Organic layer salt water washing, drying.Filtering and concentrating, column chromatography purification gets intermediate with ether-sherwood oil recrystallization: 3-(4-methyl isophthalic acid H-imidazoles-1-)-5-(trifluoromethyl)-N-(tertbutyloxycarbonyl) aniline.
To go up step intermediate (5mmol) and hydrochloric acid/Virahol (30 milliliters, 4M) and put in the reaction flask, in 60 ℃ of reactions 5 hours.Concentrating under reduced pressure removes and desolvates, and adds saturated sodium bicarbonate solution (80 milliliters), extracts salt water washing, drying with ethyl acetate (3 * 80 milliliters).Filter, concentrated doing gets intermediate 3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) aniline with ether-sherwood oil recrystallization.
Embodiment 14
6-methyl-N-[4-((4-methylpiperazine-1-yl) methyl-3-(trifluoromethyl) phenyl)-5-[4- (3-pyridyl)-2-(pyrimidyl) amino] preparation of nicotine
Method I, II in preparation method's reference example 13, difference is to change 3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) aniline (20.7 grams, 0.1mol) into 4-(4-methylpiperazine-1-yl)-3-(trifluoromethyl) aniline (25.9 grams, 0.1mol).
The preparation of intermediate 4-(4-methylpiperazine-1-yl)-3-(trifluoromethyl) aniline
Raw material 2-bromo-4-nitrotoluene (23.2mmol) is dissolved among the NMP (200 milliliters), adds sodium trifluoroacetate (8.5 grams, 62.5mmol) and the inferior ketone of iodate (8.75 grams, 46mmol), in 160 ℃ of reactions 4 hours.Cooling adds entry (300 milliliters), filters, and filter cake ether (3 * 250 milliliters) thorough washing, layering, organic layer is water, salt water washing successively, drying.Filtering and concentrating dry chromatography purifying gets 2-(trifluoromethyl)-4-nitrotoluene: 3.12 grams.
To go up step intermediate (0.5 gram, 2.44mmol) and acetate (1.9 milliliters) and put in the reaction flask, and add NBS (0.651 gram, 3.66mmol) and Benzoyl Peroxide (6 milligrams, 0.024mmol), back flow reaction is spent the night.Cooling, concentrating under reduced pressure removes and desolvates.Add ethyl acetate and saturated sodium bicarbonate solution, layering.The organic layer drying.Filter, concentrate do intermediate: 1-(brooethyl)-4-nitro-2-(trifluoromethyl) benzene.
To go up step intermediate (400 gram) and methylene dichloride (2800 milliliters) and put in the reaction flask, add triethylamine (197 milliliters) and N methyl piperazine (157 milliliters, 1.41mol), stirring at room reaction 2 hours.Add saturated solution of sodium bicarbonate, layering, the organic layer drying, the filtering and concentrating column chromatography gets intermediate: 1-[4-nitro-2-(trifluoromethyl) benzyl]-the 4-methylpiperazine.
To go up step intermediate (3.0 gram), active nickel (0.3 gram) and methyl alcohol (100 milliliters) and put in the reaction flask, atmospheric hydrogenation is to there not being raw material.Filter, concentrate and do, column chromatography gets 4-(4-methylpiperazine-1-yl)-3-(trifluoromethyl) aniline.
Embodiment 15
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[5-methyl-4-[[4-(3-pyridyl)-2-pyrimidine Base] amino] pyridyl-2-]-preparation of 3-(trifluoromethyl)-benzamide
With compound N-(methyl of 4-amino-5-picoline-2-)-4-[(4-methylpiperazine base-1-)]-3-(trifluoromethyl) benzamide (7.1 gram), 2-(methylsulfonyl)-4-(3-pyridyl) pyrimidine (5.0 gram) and DMF (50ml) put in the reaction flask; be cooled to about 0 ℃; gradation adds 60% sodium hydrogen (1.5 gram); add the back insulation reaction 2 hours, and rose to room temperature reaction 1 hour then naturally.Add 100 milliliters of the mixed solutions of chloroform/methanol=30: 1, transfer PH=7 with 10% citric acid, extraction, water layer is counter to be carried, merging organic layer, salt water washing, drying.Filter, concentrated dry chromatography purify title compound.
1. N-(methyl of 4-amino-5-picoline-2-)-4-[(4-methylpiperazine base-1-)]-3-(fluoroform Base) preparation of benzamide
Gradation adds 30% hydrogen peroxide (50ml) in aceticanhydride (50ml) solution of 2-chloro-5-picoline (10 gram), in room temperature reaction 24 hours, then 60 ℃ of reactions 30 hours.Concentrating under reduced pressure is removed excessive acetate, adds the vitriol oil (30ml) in residual solution, this solution is joined in the mixed solution of the nitric acid (50ml) and the vitriol oil (30ml), reacts half an hour in 100 ℃.Reaction solution is punched in the frozen water, transfers PH to alkalescence with volatile salt solid and ammoniacal liquor, filter intermediate: 2-chloro-4-nitro-5-methyl-nitrogen oxy picolinate.
To go up step intermediate (1.0 gram) and ammonia/ethanolic soln (20ml) of 10% and put in the reaction flask, in autoclave, be heated to back flow reaction 4 hours.Cooling, concentrating under reduced pressure is removed ethanol, adds entry, filters.Solid water recrystallization gets intermediate: 2-amino-4-nitro-5-methyl-nitrogen oxy picolinate.
To go up step intermediate (13.4 grams, 71mmol) and chloroform (150ml) and put in the reaction flask, be cooled to 0-5 ℃.In this solution, add phosphorus trichloride (19ml), be heated to 70-80 ℃ of reaction 1 hour.Cooling adds entry, transfers PH to alkalescence with sodium hydroxide solution, and chloroform extraction merges organic layer, salt water washing, drying.Filter, concentrated doing gets intermediate with the sherwood oil crystallization: 2-amino-4-nitro-5-picoline.
With the methyl of 4-[(4-methylpiperazine base-1-)]-3-(trifluoromethyl) phenylformic acid (3 grams, 10mmol) and sulfur oxychloride (50ml) put in the reaction flask, was heated to back flow reaction 5 hours.Concentrating under reduced pressure removes and desolvates, and eliminates remaining sulfur oxychloride with dry toluene band secondary.
Add pyridine (50ml) in the chloride compounds that obtains, stir adding 2-amino-4-nitro-5 picoline (1.53 grams, 10mmol) down, the stirring at room reaction is spent the night.Concentrating under reduced pressure removes and desolvates, and adds entry in residual solution, transfers PH=8 with saturated sodium bicarbonate, and chloroform extraction merges organic layer, drying.Filter, concentrate and do, column chromatography gets intermediate: N-(methyl of 4-nitro-5-picoline-2-)-4-[(4-methylpiperazine base-1-)]-3-(trifluoromethyl) benzamide.
To go up step intermediate (5.0 grams, 10mmol), hydrazine hydrate (5.4ml), methyl alcohol (180ml) and a small amount of Raney Ni and put in the reaction flask, be heated to back flow reaction 4 hours.Filter, filtrate decompression concentrates, and does with the toluene band, handles with methylene dichloride, filters, dry N-(methyl of 4-amino-5-picoline-2-)-4-[(4-methylpiperazine base-1-)]-3-(trifluoromethyl) benzamide.
Embodiment 16
5-methyl-N-[4-((4-methylpiperazine-1-yl) methyl-3-(trifluoromethyl) phenyl)-4-[4-(3-pyridine Base)-and 2-(pyrimidyl) amino] preparation of picolinamide
Method I, II in preparation method's reference example 13, difference is 6-methyl-5-[4-(3-pyridyl)-2-pyrimidinyl-amino] nicotinic acid (30.7 grams, 0.1mol) changes 5-methyl-4-[4-(3-pyridyl)-2-pyrimidinyl-amino into] Picolinic acid (30.7 grams, 0.1mol); Change 3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) aniline (24.1 grams, 0.1mol) into 4-(4-methylpiperazine-1-yl)-3-(trifluoromethyl) aniline (25.9 grams, 0.1mol).
Embodiment 17
5-methyl-N-[3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) phenyl]-4-[4-(3-pyridyl) -2-(pyrimidyl) amino] preparation of picolinamide
Method I, II in preparation method's reference example 13, difference is 6-methyl-5-[4-(3-pyridyl)-2-pyrimidinyl-amino] nicotinic acid (30.7 grams, 0.1mol) changes 5-methyl-4-[4-(3-pyridyl)-2-pyrimidinyl-amino into] pyridine carboxylic acid (Picolinic acid) (30.7 grams, 0.1mol).
Embodiment 18
Compound F 17-hydroxy-corticosterone 400g
Starch 100g
Sucrose 20g
Microcrystalline Cellulose 10g
0.5%CMC liquid is an amount of
Magnesium Stearate 5g
1000
Conventional wet granulation, compressing tablet, packing.
Experimental example one
HH-GV-E, HH-GV-F, the research of Gleevec anti tumor activity in vitro
Indicate: HH-GV-E refers to 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-chloro-benzamide mesylate;
HH-GV-F refers to 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-(trifluoromethyl)-benzamide mesylate.
1. cell strain:
HL-60: people's acute promyelocytic leukemia cell, Bcr-Abl tyrosine-kinase expression of enzymes feminine gender.
K562: people's chronic myelogenous leukemia cell, express P 210The Bcr-Abl Tyrosylprotein kinase
2. test reagent, medicine and instrument:
RPMI-1640, DMEM is available from Gibico BRL company; Foetal calf serum is available from Hyclone company; Microplate reader: POLAR star model, German BMG company product; MTT is available from Sigma.
3. test method:
The mtt assay key step:
● cell is cultivated to contain 10% foetal calf serum, makes cell be in logarithmic phase always.
● the test cell inoculation is in 96 well culture plates, and according to different cells, initial inoculation density is 4 * 10 4/ ml.37 ℃, 5%CO 2The pre-cultivation of incubator dosing in 24 hours, medicine is established 6-8 concentration, continuous action 48 hours.
● after drug effect finished, phase microscope was taken pictures.Then, every hole adds the MTT working fluid, and after 4 hours, DMSO dissolves, and measures the OD value of each aperture with the Plarstar microplate reader.
Experimental control:
The blank hole adds 20 μ l nutrient solutions, and positive control drug is selected imatinib.
Concentration is provided with:
If 5-8 concentration, each concentration are established three multiple holes.Scope is mainly at 0.001-10 μ M.
4. therapeutic evaluation:
Inhibitory rate of cell growth is calculated:
5. test-results
Imatinib (Imatinib) is brought into play the effect that it suppresses cell proliferation by the activity that suppresses the Abl Tyrosylprotein kinase.In the chronic myelogenous leukemia patient more than 95%,, cause high expression level Abl tyrosine kinase activity because chromosome translocation produces the Bcr-Abl fusion rotein.Therefore people's chronic myelogenous leukemia K562 cell expressing Bcr-Abl albumen, be the commonly used cell model of research at the Bcr-Abl medicine.This experiment finds that gained compound of the present invention all has in various degree restraining effect to the propagation of K562, and the compound F 17-hydroxy-corticosterone effect is stronger approximately 40 times than imatinib; The compd E effect is stronger 4 times than imatinib.Human promyelocytic leukemia HL-60 does not express Bcr-Abl, therefore, and as the model contrast of this experiment.Even found that gained compound of the present invention (10 μ M) when high density does not influence the propagation of HL-60 cell is also tangible, illustrate that this compounds has good selectivity to action target spot, wherein, the selectivity of control drug imatinib is approximately greater than 30 times; Compound F 17-hydroxy-corticosterone is about 1250 times; Compd E is approximately greater than 125 times.Therefore, gained compd E of the present invention and compound F 17-hydroxy-corticosterone demonstrate very strong restraining effect to target leukemia cell's propagation, and their effect all is better than or is equivalent to control drug Imatinib.(concrete outcome sees Table 1, Fig. 1, Fig. 2, Fig. 3)
Table 1 amino-metadiazine compound is to the leukemia cell's of vitro culture inhibited proliferation
Figure G60219652150141000D000191
6. conclusion
HH-GV-F, HH-GV-E demonstrates very strong restraining effect to target leukemia cell's propagation, and their effect all is better than control drug Imatinib.
Experimental example two
HH-GV-E, HH-GV-F, Gleevec are to the curative effect of human granulocyte leukemia K 562 Nude Mice
Indicate: HH-GV-E refers to 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-chloro-benzamide mesylate;
HH-GV-F refers to 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-(trifluoromethyl)-benzamide mesylate.
1. laboratory animal:
The BALB/cA-nude nude mouse is available from Shanghai Slac Experimental Animal Co., Ltd.; 18-21g, ♀, conformity certification number: SCXK (Shanghai) 2004-0005; In the SPF of constant temperature, constant humidity environment, watch foster.
2. experimental procedure:
After animal adapted to for 1 week, subcutaneous vaccination human leukemia K562 cell was treated tumor growth behind 100-300mm3, with animal random packet (d0).The nude mouse gastric infusion.HH-GV-E, Gleevec, dosage is 75mg/kg, 150mg/kg; HH-GV-F is 37.5mg/kg, 75mg/kg.Administration every day 1 time, totally 21 days.Survey the knurl volume weekly 2-3 time, claim mouse heavy, record data.Gross tumor volume (V) calculation formula is: V=1/2 * a * b2 wherein a, b represents length and width respectively.
3. result:
The mouse stomach administration, every day 1 time, continuous 21 days.
Control group mice in the time of the 18th day, has 1/8 dead mouse in experiment, has 2/8 dead mouse when experiment finishes, and according to tumor growth situation and mouse state, this death should belong to due to the tumor growth.
Gleevec does not obviously act on the K562 tumor growth according to present dosage regimen; The 150mg/kg group has the death in the 18th day after administration of 1/6 mouse, should belong to cancer-related death.
HH-GV-E 150mg/kg administration has the obvious suppression effect to the K562 tumor growth.
After the HH-GV-F 75mg/kg administration the 9th day, there is 1/6 mouse tumor regression to occur; There was 4/6 mouse tumor regression to occur on the 12nd day; 5/6 mouse tumor occurring on the 15th day disappears.But (after the administration the 21st day) has 1 mouse tumor recurrence when off-test, therefore, has 4/6 mouse tumor during off-test and disappears.37.5mg/kg administration obviously suppresses the K562 growth of tumor, but does not cause that mouse tumor disappears.The curative effect of HH-GV-F presents tangible dose-dependently.Because tumor regression, it is good that the mouse state of HH-GV-F administration group is obviously organized than control group and Gleevec, HH-GV-E, demonstrates HH-GV-F to the extraordinary result of treatment of chronic myelocytic leukemia.(concrete outcome sees Table 2, Fig. 4, Fig. 5 and Fig. 6)
The oral HH-GV-E of table 2., HH-GV-F, Gleevec are to the curative effect of human granulocyte leukemia K 562 Nude Mice
Figure G60219652150141000D000201
D0: divide the cage administration time; Dn: after the 1st administration 21 days; * P＜0.01vs contrast; CR: disappear fully.
4. conclusion:
HH-GV-F, HH-GV-E have extraordinary curative effect to the human granulocyte leukemia K 562, and its curative effect obviously is better than Gleevec.
Experimental example three
HH-GV-678, Gleevec are to the curative effect of human granulocyte leukemia K 562 Nude Mice
Indicate: HH-GV-678 (being HH-GV-F) refers to 4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-(trifluoromethyl)-benzamide mesylate.
1. laboratory animal:
The BALB/cA-nude nude mouse is available from Shanghai Slac Experimental Animal Co., Ltd.; Age in 5-6 week, ♀, conformity certification number: SCXK (Shanghai) 2004-0005; In the SPF of constant temperature, constant humidity environment, watch foster.
2. experimental procedure
After animal adapted to for 1 week, subcutaneous vaccination human leukemia K562 cell treated that tumor growth is to 100-300mm 3After, with animal random packet (d0).Nude mouse is irritated stomach HH-GV-678, Gleevec, and it is 75mg/kg that dosage is respectively HH-GV-678,150mg/kg; Gleevec is 150mg/kg.HH-GV-678 administration every day 1 time, totally 21 days.Gleevec every day 2 times, each 150mg/kg, totally 21 days.Survey the knurl volume weekly 2-3 time, claim mouse heavy, record data.Gross tumor volume (V) calculation formula is: V=1/2 * a * b 2Wherein a, b represent length and width respectively.
3. result:
HH-GV-678 group 75mg/kg administration at the 6th day, promptly has 3/8 mouse tumor disappear fully (CR); To the 9th day, there is 7/8 mouse tumor to occur disappearing fully.In the time of the 12nd day, all tumours (8/8) all disappear.
HH-GV-678 group 150mg/kg administration in the time of the 6th day, promptly has 6/8 mouse tumor (CR) to occur disappearing fully; In the time of the 9th day, all tumours (8/8) all disappear fully.
Gleevec group the 12nd day the time, has 1/8 mouse tumor to occur disappearing fully after administration; When finishing, there is 2/8 mouse tumor to occur disappearing fully to experiment.
Experimental results show that the HH-GV-678 onset is very fast, and the Gleevec onset is relatively slow; And the curative effect of HH-GV-678 obviously is better than Gleevec.
Tumor-bearing mice all can tolerate well to above 2 compounds, and comparatively speaking, under this experiment condition, the toxicity of HH-GV-678 is less.(concrete outcome sees Table 3, Fig. 7 and Fig. 8)
The oral HH-GV-678 of table 3., Gleevec are to the curative effect of human granulocyte leukemia K 562 Nude Mice
Figure G60219652150141000D000211
Figure G60219652150141000D000221
D0: divide the cage administration time; Dn: after the 1st administration 21 days; * P＜0.01vs contrast; CR: disappear fully.
4. conclusion:
HH-GV-678 and Gleevec all have significant curative effect to the human granulocyte leukemia K 562; The curative effect of HH-GV-678 obviously is better than Gleevec; Comparatively speaking, under this experiment condition, the toxicity of HH-GV-678 is slightly less than Gleevec.

Claims (29)

1. an amino-metadiazine compound and pharmacy acceptable salt thereof that general formula is (I):
In the formula,
R 1Be selected from optional substituted phenyl or 4-8 unit monocyclic heterocycles, substituting group is selected from halogen atom, C 1-4Straight or branched alkyl, amino, C 1-10Alkoxyl group;
R 2And R 3Be independently selected from hydrogen, halogen atom, amino, C 1-10Alkylamino, two C 1-10Alkylamino, cyano group, nitro, hydroxyl, C 1-10Alkoxyl group, halo C 1-10Alkoxyl group;
R 4Be selected from hydrogen, halogen atom, amino, C 1-10Alkylamino, two C 1-10Alkylamino, cyano group or optional substituted C 1-10Alkyl, C 3-10Cycloalkyl, C 2-10Thiazolinyl, C 2-10Alkynyl, substituting group are selected from halogen atom, amino, hydroxyl;
R 5Be selected from hydrogen, halogen atom, nitro, cyano group, hydroxyl, C 1-10Alkoxyl group, methylene-dioxy, halo C 1-10Alkoxyl group, amino or optional substituted C 1-10Alkyl, C 3-10Cycloalkyl, C 2-10Thiazolinyl, C 2-10Alkynyl, substituting group are selected from halogen atom, amino, hydroxyl;
R 6Be selected from hydrogen or optional substituted C 1-10Alkyl, C 3-10Cycloalkyl, phenyl, phenyl-C 1-10Alkyl, heterocyclic aryl, heterocyclic aryl-C 1-10Alkyl, 4-8 unit monocyclic heterocycles, the monocyclic heterocycles-C of 4-8 unit 1-10Alkyl, substituting group are selected from halogen atom, amino, C 1-4Alkyl;
M=0,1,2 or 3;
N=0,1,2 or 3;
Q is selected from pyridyl;
Z is selected from phenyl, heterocyclic aryl or 4-8 unit monocyclic heterocycles;
L is selected from-NR 7CO-,-CONR 8-, NR 9SO 2-,-SO 2NR 10-,-NR 11COO-,-NR 12CONR 13-,-OCONR 14-;
R wherein 7, R 8, R 9, R 10, R 11, R 12, R 13And R 14Be selected from hydrogen, optional substituted C 1-10Alkyl, C 3-10Cycloalkyl, substituting group are selected from halogen atom, amino, hydroxyl;
Wherein, heterocyclic aryl is represented stable monocycle or dicyclo, and wherein each ring carbon atom is not more than 7 and at least one ring for aromatic nucleus and contain 1-4 heteroatoms that is selected from O, N, S.
2. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that R in the described compound 1Be selected from optional substituted pyridyl, substituting group is selected from halogen atom, C 1-4The straight or branched alkyl.
3. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that R in the described compound 2And R 3Be independently from each other hydrogen, halogen atom, amino, C 1-10Alkylamino, cyano group or nitro.
4. compound according to claim 3 and pharmacy acceptable salt thereof is characterized in that R in the described compound 2And R 3Be independently from each other hydrogen or halogen atom, wherein halogen atom is selected from fluorine, chlorine, bromine or iodine atom.
5. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that R in the described compound 4Be selected from optional substituted C 1-10Alkyl, C 2-10Thiazolinyl or C 2-10Alkynyl, substituting group are selected from halogen atom or amino.
6. compound according to claim 5 and pharmacy acceptable salt thereof is characterized in that R in the described compound 4Be selected from optional substituted C 1-10Alkyl, substituting group are selected from halogen atom or amino.
7. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that R in the described compound 5Be selected from hydrogen, halogen atom, nitro, optional substituted C 1-10Alkyl, C 3-10Cycloalkyl, C 2-10Thiazolinyl, C 2-10Alkynyl, substituting group are selected from halogen atom or hydroxyl.
8. compound according to claim 7 and pharmacy acceptable salt thereof is characterized in that R in the described compound 5Be selected from hydrogen, halogen atom or optional substituted C 1-10Alkyl, C 3-10Cycloalkyl, substituting group are selected from halogen atom or hydroxyl.
9. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that R in the described compound 6Be selected from optional substituted heterocyclic aryl, heterocyclic aryl-C 1-10Alkyl, 4-8 unit's monocyclic heterocycles and the monocyclic heterocycles-C of 4-8 unit 1-10Alkyl, substituting group are selected from halogen atom or C 1-4Alkyl; Wherein, heterocyclic aryl is represented stable monocycle or dicyclo, and wherein each ring carbon atom is not more than 7 and at least one ring for aromatic nucleus and contain 1-4 heteroatoms that is selected from O, N, S.
10. compound according to claim 9 and pharmacy acceptable salt thereof is characterized in that R in the described compound 6Be selected from optional substituted heterocyclic aryl, the monocyclic heterocycles-C of 4-8 unit 1-10Alkyl, substituting group are C 1-4Alkyl; Wherein, heterocyclic aryl is represented stable monocycle or dicyclo, and wherein each ring carbon atom is not more than 7 and at least one ring for aromatic nucleus and contain 1-4 heteroatoms that is selected from O, N, S.
11. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that m and n are independently selected from 0,1,2 in the described compound.
12. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that L is selected from-NR in the described compound 7CO-,-CONR 8-,-NR 9SO 2-,-SO 2NR 10-,-NR 11COO-, wherein R 7, R 8, R 9, R 10, R 11Be hydrogen.
13. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that L is-NR in the described compound 7CO-or-CONR 8-, R wherein 7, R 8Be hydrogen.
14. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that in the described compound:
R 1Be selected from optional substituted phenyl, pyridyl, substituting group is selected from halogen atom, C 1-4Straight or branched alkyl, amino, C 1-10Alkoxyl group;
R 2And R 3Be independently selected from hydrogen, halogen atom, amino, C 1-10Alkylamino, two C 1-10Alkylamino, cyano group, nitro, hydroxyl, C 1-10Alkoxyl group, halo C 1-10Alkoxyl group;
R 4Be selected from hydrogen, halogen atom, amino, C 1-10Alkylamino, two C 1-10Alkylamino, cyano group or optional substituted C 1-10Alkyl, substituting group are selected from halogen atom, amino, hydroxyl;
R 5Be selected from hydrogen, halogen atom, nitro, cyano group, hydroxyl, C 1-10Alkoxyl group, amino or optional substituted C 1-10Alkyl, C 3-10Cycloalkyl, substituting group are selected from halogen atom, amino, hydroxyl;
R 6Be selected from optional substituted heterocyclic aryl, heterocyclic aryl-C 1-10Alkyl, 4-8 unit monocyclic heterocycles, the monocyclic heterocycles-C of 4-8 unit 1-10Alkyl, substituting group are selected from halogen atom, amino, C 1-4Alkyl;
M=0 or 1;
N=0 or 1;
Q is selected from pyridyl;
Z is selected from phenyl;
L is selected from-NR 7CO-,-CONR 8-;
R wherein 7, R 8Be selected from hydrogen, optional substituted C 1-4Alkyl, C 3-10Cycloalkyl, substituting group are selected from halogen atom, amino, hydroxyl;
Wherein, heterocyclic aryl is represented stable monocycle or dicyclo, and wherein each ring carbon atom is not more than 7 and at least one ring for aromatic nucleus and contain 1-4 heteroatoms that is selected from O, N, S.
15. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that described compound and sour salify, used acid is selected from organic acid or mineral acid.
16. compound according to claim 15 and pharmacy acceptable salt thereof, it is characterized in that organic acid is selected from acetate, trichoroacetic acid(TCA), propionic acid, butyric acid, aspartic acid, tosic acid, methylsulfonic acid, toxilic acid, lactic acid, mineral acid comprises hydrochloric acid, sulfuric acid, phosphoric acid.
17. compound according to claim 16 and pharmacy acceptable salt thereof is characterized in that acid is hydrochloric acid or methylsulfonic acid.
18. compound according to claim 15 and pharmacy acceptable salt thereof, it is characterized in that described compound and etc. the sour salify of amount.
19. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that described compound and alkali salify, the salt that is become is selected from the salt that become with basic metal, alkaline-earth metal or quaternary ammonium.
20. compound according to claim 19 and pharmacy acceptable salt thereof is characterized in that described quaternary ammonium is NY 4, wherein Y refers to that carbon atom is the alkyl of 1-4.
21. compound according to claim 1 and pharmacy acceptable salt thereof is characterized in that described compound is selected from following compound:
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-] benzamide,
4-((4-ethyl-1-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-] benzamide,
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-fluoro-benzamide,
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-chloro-benzamide,
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[6-methyl-5-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-3-]-3-(trifluoromethyl)-benzamide,
6-methyl-N-[3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) phenyl]-5-[4-(3-pyridyl)-2-(pyrimidyl) amino] nicotine,
6-methyl-N-[4-((4-methylpiperazine-1-yl) methyl-3-(trifluoromethyl) phenyl)-5-[4-(3-pyridyl)-2-(pyrimidyl) amino] nicotine,
4-((4-methyl isophthalic acid-piperazinyl) methyl)-N-[5-methyl-4-[[4-(3-pyridyl)-2-pyrimidyl] amino] pyridyl-2-]-3-(trifluoromethyl)-benzamide,
5-methyl-N-[4-((4-methylpiperazine-1-yl) methyl-3-(trifluoromethyl) phenyl)-4-[4-(3-pyridyl)-2-(pyrimidyl) amino] picolinamide,
5-methyl-N-[3-(4-methyl isophthalic acid H-imidazoles-1-yl)-5-(trifluoromethyl) phenyl]-4-[4-(3-pyridyl)-2-(pyrimidyl) amino] picolinamide.
22. a method for preparing described compound of claim 1 and pharmacy acceptable salt thereof, its feature comprises the steps:
(A) under alkaline condition, react to such an extent that general formula is the compound of (IV) for the compound of (II) and general formula for the compound of (III) general formula;
(B) general formula is got the compound that general formula is (I) for the compound of (IV) and general formula for compound condensation reaction in the presence of condensing agent of (V);
R wherein 1, R 2, R 3, R 4, R 5, R 6, Q, L, Z, m, n as defined in claim 1; L ', M ' refer to the group of phase mutual energy generation condensation reaction, and this group is selected from amino, carboxylic acid group, acid halide group, or refer to can change into through conventional method the organic group of amino, carboxylic acid group or acid halide group; R 15Refer to easy leavings group, it is selected from halogen atom or methylsulfonyl, ethylsulfonyl, p-toluenesulfonyl.
23. according to the described preparation general formula of claim 22 is the method for the compound and the pharmacy acceptable salt thereof of (I), it is characterized in that: described organic group is selected from nitro or ester group.
24. according to the described preparation general formula of claim 23 is the method for the compound and the pharmacy acceptable salt thereof of (I), it is characterized in that:
(A) when preparation compound (IV), use alkali, described alkali is selected from organic bases or mineral alkali, and this organic bases is selected from n-Butyl Lithium, sodium methylate, sodium ethylate, potassium tert.-butoxide, and this mineral alkali is selected from sodium hydroxide, potassium hydroxide, sodium amide, sodium hydrogen;
(B) when preparation compound (I), when reaction is carboxylic acid group and amino condensation, condensing agent is N, N-dicyclohexylcarbodiimide, N, N-DIC, N, the mixture that mixture that N-diethyl carbodiimide, triphenyl phosphorus and diethylazodicarboxylate form or triphenyl phosphorus and diisopropyl azo-2-carboxylic acid form; When reaction was acid halide group and amino condensation, condensing agent was mineral alkali or organic bases.
25. according to the described preparation general formula of claim 24 is the method for the compound and the pharmacy acceptable salt thereof of (I), it is characterized in that:
(A) when preparation compound (IV), described mineral alkali is a sodium hydrogen;
(B) when preparation compound (I), when reaction was carboxylic acid group and amino condensation, described condensing agent was N, the N-dicyclohexylcarbodiimide; When reaction was acid halide group and amino condensation, described condensing agent was pyridine or triethylamine.
26. according to the described preparation general formula of claim 24 is the method for the compound and the pharmacy acceptable salt thereof of (I), it is characterized in that: when preparation compound (I), described mineral alkali is selected from yellow soda ash, salt of wormwood, lime carbonate, and organic bases is selected from triethylamine, pyridine, 4-dimethylamino pyridine, tripropyl amine, Tributylamine.
27. described compound of claim 1 and pharmacy acceptable salt thereof the application in the preparation kinases inhibitor.
28. compound as claimed in claim 1 and pharmacy acceptable salt thereof the application in preparation treatment cell hyperplastic disease medicine.
29. one kind contains the compound as claimed in claim 1 of medicine effective dose and the pharmaceutical composition of salt and pharmaceutically acceptable carrier thereof.
CN2005800208831A 2004-12-31 2005-12-26 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof Active CN1972917B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN200410103077.8 2004-12-31
CN200410103077 2004-12-31
CN200510107402.2 2005-09-30
CNA2005101074022A CN1939910A (en) 2004-12-31 2005-09-30 Amino-metadiazine compound and its salt, its preparation and pharmaceutical use
PCT/CN2005/002308 WO2006069525A1 (en) 2004-12-31 2005-12-26 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
CN1972917A CN1972917A (en) 2007-05-30
CN1972917B true CN1972917B (en) 2010-08-25

Family

ID=38113141

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800208831A Active CN1972917B (en) 2004-12-31 2005-12-26 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof

Country Status (1)

Country Link
CN (1) CN1972917B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816146A (en) * 2011-06-10 2012-12-12 江苏豪森医药集团连云港宏创医药有限公司 Flumatinib mesylate crystal form A and preparation method and use thereof
CN103420976A (en) * 2013-07-26 2013-12-04 天津禾盛医药技术开发有限公司 Method for preparing imatinib and mesylate
CN103509007A (en) * 2012-06-19 2014-01-15 江苏豪森医药集团连云港宏创医药有限公司 Flumatinib mesylate crystal form and preparation method and use thereof
CN103509006A (en) * 2012-06-19 2014-01-15 江苏豪森医药集团连云港宏创医药有限公司 Flumatinib mesylate crystal form, and preparation method and use thereof
CN104974139A (en) * 2014-04-04 2015-10-14 江苏豪森药业股份有限公司 Novel crystal form of flumatinib mesylate as well as preparation method and medical use of novel crystal form
CN105198860A (en) * 2014-06-12 2015-12-30 江苏豪森药业股份有限公司 Novel flumatinib mesylate crystal form and preparation method and application thereof
CN107648237A (en) * 2016-07-26 2018-02-02 江苏豪森药业集团有限公司 Pharmaceutical composition of amino-metadiazine compound and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153974A1 (en) * 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1043531C (en) * 1992-04-03 1999-06-02 诺瓦提斯公司 Pyrimidine derivatives and a process for production thereof
CN1525967A (en) * 2000-09-13 2004-09-01 ��˹��ŵ�� N-phenyl-2-pyrimidine-amine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1043531C (en) * 1992-04-03 1999-06-02 诺瓦提斯公司 Pyrimidine derivatives and a process for production thereof
CN1525967A (en) * 2000-09-13 2004-09-01 ��˹��ŵ�� N-phenyl-2-pyrimidine-amine derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
MEDICINAL CHEMISTRY LETTERS,OXFORD,GB,6 11.1996,1221-1226, 参见表1, 特别是化合物1、4-10、12和14-16. *
MEDICINAL CHEMISTRY LETTERS,OXFORD,GB7 2.1997,7(2),187-192, 参见表1, 特别是化合物1-8、11、12、14、15、19、21、30和32. *
ZIMMERMANN J ET AL.Phenylamino-pyrimidine (PAP) - derivatives: a newclassofpotent and highlyselectivePDGF-receptorautophosphorylation inhibitors.BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB,6 11.1996,1221-1226, 参见表1, 特别是化合物1、4-10、12和14-16.
ZIMMERMANN J ET AL.Phenylamino-pyrimidine (PAP)-derivatives: a newclassofpotent and highlyselectivePDGF-receptorautophosphorylation inhibitors.BIOORGANIC &amp *
ZIMMERMANN J ET AL.Potent and selective inhibitorsoftheAbl-kinase:phenylamino-pyrimidine (PAP)derivatives.BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB7 2.1997,7(2),187-192, 参见表1, 特别是化合物1-8、11、12、14、15、19、21、30和32.
ZIMMERMANN J ET AL.Potent and selective inhibitorsoftheAbl-kinase:phenylamino-pyrimidine (PAP)derivatives.BIOORGANIC &amp *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816146A (en) * 2011-06-10 2012-12-12 江苏豪森医药集团连云港宏创医药有限公司 Flumatinib mesylate crystal form A and preparation method and use thereof
CN103509007A (en) * 2012-06-19 2014-01-15 江苏豪森医药集团连云港宏创医药有限公司 Flumatinib mesylate crystal form and preparation method and use thereof
CN103509006A (en) * 2012-06-19 2014-01-15 江苏豪森医药集团连云港宏创医药有限公司 Flumatinib mesylate crystal form, and preparation method and use thereof
CN103509007B (en) * 2012-06-19 2016-08-31 江苏豪森药业集团有限公司 Methanesulfonic acid fluorine imatinib crystal formation and its production and use
CN103509006B (en) * 2012-06-19 2016-11-16 江苏豪森药业集团有限公司 Methanesulfonic acid fluorine imatinib crystal formation and its production and use
CN103420976A (en) * 2013-07-26 2013-12-04 天津禾盛医药技术开发有限公司 Method for preparing imatinib and mesylate
CN104974139A (en) * 2014-04-04 2015-10-14 江苏豪森药业股份有限公司 Novel crystal form of flumatinib mesylate as well as preparation method and medical use of novel crystal form
CN104974139B (en) * 2014-04-04 2019-09-06 江苏豪森药业集团有限公司 Methanesulfonic acid fluorine imatinib novel crystal forms and preparation method thereof and medical usage
CN105198860A (en) * 2014-06-12 2015-12-30 江苏豪森药业股份有限公司 Novel flumatinib mesylate crystal form and preparation method and application thereof
CN107648237A (en) * 2016-07-26 2018-02-02 江苏豪森药业集团有限公司 Pharmaceutical composition of amino-metadiazine compound and preparation method thereof
CN107648237B (en) * 2016-07-26 2022-03-04 江苏豪森药业集团有限公司 Pharmaceutical composition of aminopyrimidine compounds and preparation method thereof

Also Published As

Publication number Publication date
CN1972917A (en) 2007-05-30

Similar Documents

Publication Publication Date Title
CN1972917B (en) Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
EP1840122B1 (en) Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
ES2865374T3 (en) Isoquinolin-3-yl carboxamides and their preparation and use
AU2006212761B2 (en) Combination therapy
CN102015686B (en) Novel heterocyclic compounds and uses therof
KR20190080897A (en) Substituted pyridinone-containing tricyclic compounds, and methods of use thereof
JP5756518B2 (en) Heterocyclic alkynylbenzene compounds and their medical compositions and uses
AU2011217489B2 (en) Pyrazole derivatives as JAK inhibitors
CN101883764B (en) Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
CA2961412C (en) Inhibiting the transient receptor potential a1 ion channel
CN101568529A (en) Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
TW202144345A (en) Kras mutant protein inhibitors
WO2012087938A1 (en) Quinazolinone derivatives as antiviral agents
CN101568530A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
KR20130142153A (en) Heterocycle amines and uses thereof
TW201639828A (en) 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CN105636958A (en) Dna-pk inhibitors
CA2935867A1 (en) Heteroaryls and uses thereof
CN103202842A (en) Methods Of Treating By Inhibiting With Quinaxoline Inhibitors Of P13k-alpha
TW200530235A (en) Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
CN103864792A (en) Heterocyclic nitrogen compound acting as tyrosine kinase inhibitor
CN103539777A (en) PI3 kinase regulator as well as use method and application of PI3 kinase regulator
CN102482272A (en) Therapeutic agent for mood disorders
CN103224496A (en) Tricyclic PI3K and/or mTOR inhibitors
CN103214481A (en) Novel imidazo[1,2-a]pyridines compound, preparation method, pharmaceutical composition containing imidazo[1,2-a]pyridines compound and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1095146

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: HONGCHUANG MEDICAL SCIENCE + TECHNOLOGY CO., LTD.,

Free format text: FORMER OWNER: SUN PIAOYANG

Effective date: 20110929

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 222000 LIANYUNGANG, JIANGSU PROVINCE TO: 214072 WUXI, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20110929

Address after: 214072 Jiangsu province Binhu District of Wuxi City Liyuan Economic and Technological Development Zone

Patentee after: Hongchuang Medical Science & Technology Co., Ltd., Wuxi

Address before: 222000, No. 145, Renmin East Road, Sinpo District, Jiangsu, Lianyungang, China

Patentee before: Sun Piaoyang

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160413

Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL CO., LTD.

Address before: 214072 Jiangsu province Binhu District of Wuxi City Liyuan Economic and Technological Development Zone

Patentee before: Hongchuang Medical Science & Technology Co., Ltd., Wuxi

CB03 Change of inventor or designer information

Inventor after: Lv Aifeng

Inventor after: Yang Baohai

Inventor after: Hu Chunyong

Inventor before: Sun Piaoyang

Inventor before: Lv Aifeng

Inventor before: Yang Baohai

Inventor before: Hu Chunyong

CB03 Change of inventor or designer information